Brought to you by 
CRT grants Scancell exclusive antibody rights
19 Aug 2010
Executive Summary
Cancer Research Technology (CRT) has granted cancer vaccine developer Scancell Holdings PLC exclusive worldwide rights to use the 105AD7 antibody in new immunotherapy vaccines.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CRT grants Scancell exclusive antibody rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice